At the news
? BULLISHIMPACT 8/10 COURT-RULING filed Apr 15, 2026 at 20:00 ET
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment invalidating Teva's headache-related patents, reinstating a jury verdict that Eli Lilly willfully infringed the patents. This strengthens Teva's IP position and may lead to damages or licensing revenue.
- Federal Circuit reversed lower court's invalidation of Teva's U.S. Patent Nos. 8,586,045, 9,884,907, and 9,884,908
- Appellate court reinstated jury finding that Eli Lilly willfully infringed the patents
- Ruling affirms validity of Teva's patents covering use of humanized anti-CGRP antagonist antibodies to treat headache
- Case remanded for further proceedings consistent with the opinion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access